sanofi-aventis (SNY) April 25, 2012 9:00 am ET Executives Sébastien Martel - William J. Sibold - Head of Multiple Sclerosis Business and Senior Vice President Michael Panzara - Alasdair Coles - Jeffrey Cohen - Analysts Richard J. Parkes - Deutsche Bank AG, Research Division Peter Verdult - Morgan Stanley, Research Division Mark Dainty - Citigroup Inc, Research Division Vincent Meunier - Exane BNP Paribas, Research Division Richard Vosser - JP Morgan Chase & Co, Research Division Philippe Lanone - Natixis Bleichroeder LLC, Research Division Michael Leuchten - Barclays Capital, Research Division Unknown Analyst PresentationOperator
Welcome to the Sanofi Conference Call on Multiple Sclerosis. I now hand you over to Mr. Sébastien Martel, Head of Investor Relations. Sir, please go ahead. Sébastien Martel Thank you. Hello, everyone, and welcome to our IR Thematic Call on Multiple Sclerosis. This call is made to provide you with an update on Genzyme's MS portfolio and in particular, Lemtrada. Indeed, we're here in the middle of the American Academy of Neurology meeting in New Orleans. And following the release of detailed results from CARE-MS II yesterday, we believe that it was important that we provide investors and analysts with an overview of Lemtrada's profile for CARE-MS studies. As always, we've prepared a presentation for the call, and our slides are available to download from our website. As you know, I must advise you that the information presented on this conference call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to differ materially. Please refer to our Form 20-F on file with the SEC and also, our Document de Reference for description of these factors.